NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Geron Corp. GERN
17 fiscal years on record · USD · FY2025 reported · SEC filings only
$-83.5M
Growth
—
Revenue, FY2025 · full 17-year series below
Revenue $M
Net income $M
FY2023 · Revenue 0.2 · Net income -184.1
Compound annual growth
Revenue compounded at −26.0% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2023 · Operating -81832.9% · Net -77690.7%
ROE
FY2025 · ROE -33.0%
Each USD of equity lost 33 cents this year.
The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 |
| EBITDA $B | · | · | · | · | · | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Net income $B | −0.1 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 |
| Free cash flow $B | · | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | · | −0.0 | −0.0 | 0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 |
| EPS, diluted $ | −0.13 | −0.27 | −0.32 | −0.37 | −0.35 | −0.28 | −0.36 | −0.15 | −0.18 | −0.19 | 0.00 | −0.23 | −0.30 | −0.54 | −0.78 | −1.14 | −0.80 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | 0 | −0 | −0 | · | · | · | · |
| ROE % | −33.0 | −66.1 | −112.3 | −137.5 | −68.8 | −43.7 | −43.8 | −19.2 | −24.7 | −22.3 | 0.0 | −37.5 | −52.8 | −59.3 | −57.1 | −61.0 | −40.7 |
| Shares out B | 0.64 | 0.61 | 0.54 | 0.39 | 0.32 | 0.31 | 0.20 | 0.19 | 0.16 | 0.16 | 0.16 | 0.16 | 0.13 | 0.13 | 0.13 | 0.12 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 64 reconciliationsAUDITED
Reconciled in 17 of 19 fiscal years. 12 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009